Management baked in 25-35% quarterly script growth in their full year guidance
Latest week Symphony scripts = 412
4 week ago scripts were 350
(412/350) ^ (13/4) -1 = 70% quarterly script growth rate
Newly trained sales force & increasing physicial comport seems to be resulting in script acceleration that will drive revenue beats and upward revisions
Should be a formula for a good stock this year!!!!
Shorts run for cover Less
Sentiment: Strong Buy
over the past 4 weeks, scripts are growing at a 70% quarter to quarter growth rate... management guidance assumed 25-35% quarterly growth rate... so if the recent trend continues, there should be nice upside to numbers! a good formula for the stock to work.
Quitcher btchin, its not too late to buy back your shares and recoup your lose. H3ll your here everyday so why not be a shareholder?
Look who' talkin. The resident idiot who wants to heard and contribute but does not have the intelligence to put an original thought together. Lololol.
Should be north of 1000 by now, north of 4000 per month, out of 50,000 per month, easy, wattsdamatta wit u !...,
They are really low balling the revenue guidance. If the Japanese royalty payments stay flat at $1.2 million and they grow script revenue by 17% per quarter, then 2016 revenue would be $33.5 million: right smack in the middle of their guidance, which would be pathetic.
If, a big if, they ever execute decent growth, they should raise revenue guidance mid-year. .
Slow but Steady - - Broke 400 TRX for second time, but most encouraging is continued increase from Refills (RRX 217) - - Continued use is strong indication of efficacy and minimal side effects.
That actually makes what you're buying a lot more expensive. A lot. Better off just holding top. So if you have a stock that's 3. you own it starting at 4. You sell the 4. and buy it back at 3. It costs you the difference between the 3 and 4, so the stock ends up costing you 4 plus commission. Gaining nothing.
Yes, Fexeric in Europe approved for dialysis and pre-dialysis patients...Although not for IDA, only for hyperphosphatemia, one could say that nephrologists will prescribe drug based on full range of benefits...
Maybe not necessary to pursue IDA label in Europe, no ?...P3 results could be used as 'U.S experience' in educational efforts of sorts i.e. full range of benefits, no ?...